CAMBRIDGE, Massachusetts, January 31, 2022 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) approved Vonvendi® [von Willebrand factor…Original Article
FDA Approves Prophylactic Treatment with Vonvendi [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
